SPDR S&P Biotech ETF (NYSE:XBI) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the “index”), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (“S&P TMI”).
SPDR S&P Biotech ETF seeks to provide investment results that correspond to the total return performance of the S&P Biotechnology Select Industry Index.
- Net Assets 7.36 Billions
- 1-Year Daily Total Return 12.17%
- Yield 0.23%
- Annual Expense Ratio 0.35%
This ETF has modified equal-weighted index which provides exposure to large, mid, and small-cap stocks in the biotech ecosystem. XBI’s equal weight structure gives investors “unconcentrated exposure” to 172 biotech companies. This includes the smaller, more risky drug manufacturers who can see their share price rise or fall dramatically depending on approvals (or rejections) from the FDA.
Top 10 Holdings (8.60% of Total Assets)
XBI is one of the better Biotech ETF.
XBI is one of the best ETF.
Good ETF to own for this decade
I own XBI ETF for biotech stocks.